Supernus Pharmaceuticals | SUPN - Selling And Administration Expenses

Stock Price
50.86
Daily Change
-0.49 -0.95%
Monthly
2.71%
Yearly
53.89%
Q1 Forecast
49.28

Supernus Pharmaceuticals reported $179.68M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
ANI Pharmaceuticals USD 76.66M 5.11M Sep/2025
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Cara Therapeutics USD 4.64M 2.19M Mar/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Eisai JPY 111.72B 7.86B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Novo Nordisk DKK 17.44B 1.41B Dec/2025
Pacira USD 91.8M 14.6M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025
United Therapeutics USD 152M 60.5M Sep/2025
Xeris Pharmaceuticals USD 46.46M 2.07M Sep/2025